Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus HL-200
- Development stage
- Preclinical
- Lead developer
- University of South Florida
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus HL-200 is a specific human-derived probiotic bacterial strain being developed as a **microbial therapy** for disorders associated with increased intestinal permeability and metabolic inflammation, including obesity-related leaky gut and type 2 diabetes-associated gut barrier dysfunction. Publicly available patent and technology-transfer materials describe HL-200 as a high ethanolamine-metabolizing *L. rhamnosus* strain that counteracts ethanolamine accumulation in the gut and is proposed to restore intestinal tight-junction integrity through the ARID3a/miR-101a-3p/Tjp1 axis, thereby reducing gut permeability and downstream inflammatory signaling. The program appears to originate from University of South Florida-associated investigators, with evidence in preclinical mouse studies and patent filings rather than registered clinical development. This is a strain-specific probiotic candidate rather than a conventional pharmaceutical small molecule or biologic.
- Other names
- Lactobacillus rhamnosus HL-200human-origin probiotic Lactobacillus rhamnosus HL-200
Beyond the preview
Go deeper on Lactobacillus rhamnosus HL-200.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus HL-200.